Quantum News
Sign InSign Up
Back to News
research

Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Galectin Therapeutics presented updated clinical results for belapectin, a drug targeting MASH cirrhosis with portal hypertension, during a March 2026 virtual event featuring top hepatologists. Chief Medical Officer Khurram Jamil highlighted belapectin’s potential to address a critical unmet need in treating advanced liver fibrosis, emphasizing its mechanism targeting galectin-3 pathways. Key opinion leaders Dr. Naga Chalasani (Indiana University) and Dr. Naim Alkhouri (Summit Clinical Research) joined to discuss the drug’s clinical progress and therapeutic promise for high-risk patients. The event focused on belapectin’s latest trial data, suggesting potential efficacy in reducing portal hypertension—a life-threatening complication of MASH cirrhosis with limited treatment options. A Q&A session followed, allowing experts to address clinical and regulatory questions, reinforcing belapectin’s role as a potential breakthrough in liver disease management.
AI Audio Summary
0:00 / 0:00
Click to play
Untitled design (22).png
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts158.9K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension March 10, 2026 12:00 PM EDT Company Participants Khurram Jamil - Chief Medical OfficerNaga Chalasani Conference Call Participants Tara SobierajskiMichael CozartNaim Alkhouri Presentation Tara Sobierajski Good afternoon, and welcome to the Galectin Therapeutics Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Galectin website following the conclusion of the event. I'd now like to turn the call over to your moderator, Michael Cozart of LifeSci Consulting. Please go ahead, Michael.

Michael Cozart Thanks, Tara, and good afternoon, everyone, and thank you for joining today's KOL webinar. My name is Michael Cozart, and I'm Managing Partner at LifeSci Consulting. Today, we will discuss belapectin as a treatment for MASH cirrhosis with portal hypertension. Joining today's call, in addition to Galectin management are two leading key opinion leaders, Dr. Naga Chalasani, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell Biology and Physiology and Director of the Terance Kahn Liver Research Program at Indiana University School of Medicine; and Dr. Naim Alkhouri, Chief Academic Officer at Summit Clinical Research in San Antonio and the Director of Steatotic Liver Program at North Shore Gastroenterology in Cleveland. As Tara mentioned, today's call will include a brief Q&A session should time allow. And as we get started here, we'd like to introduce Khurram Jamil, Galectin's Chief Medical Officer, who will provide not only a brief overview of MASH cirrhosis with portal hypertension, but also belapectin's ability to address this significant unmet medical need. So with that, Khurram, I will turn it over to you. Khurram JamilChief Medical Officer Thank you, Michael. Yes, I'm really excited to join two distinguished experts today as we

Read Original

Tags

quantum-algorithms

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.